LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Accueil・Liste d'Actions・Ovid therapeutics Inc

Ovid therapeutics Inc

Fermé

SecteurSoins de santé

2.38 -3.64

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.36

Max

2.41

Chiffres clés
By Trading Economics
Revenu	-27M -17M
BPA	-0.125
Marge bénéficiaire	-2,366.017
Employés	23
EBITDA	-5.5M -18M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+114.92% upside

Dividendes
By Dow Jones
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-5M 478M
Ouverture précédente	6.02
Clôture précédente	2.38

Sentiment de l'Actualité

By Acuity

50%

155 / 344 Classement par Healthcare

Ovid therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juin 2026, 19:20 UTC

Principaux Mouvements du Marché

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 juin 2026, 21:27 UTC

Résultats

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 juin 2026, 20:19 UTC

Acquisitions, Fusions, Rachats

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 juin 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 juin 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 juin 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 juin 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 juin 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 juin 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 juin 2026, 18:33 UTC

Acquisitions, Fusions, Rachats

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 juin 2026, 17:50 UTC

Résultats

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 juin 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 juin 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 juin 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 juin 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2026, 15:44 UTC

Acquisitions, Fusions, Rachats

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 juin 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 juin 2026, 15:25 UTC

Résultats

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 juin 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 juin 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 juin 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 juin 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 juin 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparaison

Variation de prix

Ovid therapeutics Inc prévision

Objectif de Prix

By TipRanks

114.92% hausse

Prévisions sur 12 Mois

Moyen 5.33 USD 114.92%

Haut 7 USD

Bas 4 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

155 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.